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ORIGINAL RESEARCH
Effect of Alteplase Use on Outcomes in 
Patients With Atrial Fibrillation: Analysis 
of the Initiation of Anticoagulation After 
Cardioembolic Stroke Study
Shadi Yaghi , MD*; Eva Mistry , MBBS*; Adam de Havenon , MD; Christopher R. Leon Guerrero, MD; 
Amre Nouh, MD; Ava L. Liberman , MD; James Giles , MD; Angela Liu, MD; Muhammad Nagy, MD; 
Ashutosh Kaushal, MD; Idrees Azher, MD; Brian Mac Grory , MD; Hiba Fakhri, BS; Kiersten Brown Espaillat, RN; 
Syed Daniyal Asad , MD; Hemanth Pasupuleti, MD; Heather Martin, BS; Jose Tan, MD;  
Manivannan Veerasamy , MD; Charles Esenwa , MD; Natalie Cheng, MD; Khadean Moncrieffe , BS;  
Iman Moeini- Naghani, MD; Mithilesh Siddu, MD; Erica Scher, MPH; Tushar Trivedi , MD, MPH;  
Teddy Wu , MD; Muhib Khan, MD; Salah Keyrouz, MD; Karen Furie , MD; Nils Henninger , MD, PhD
BACKGROUND: Intravenous alteplase improves outcome after acute ischemic stroke without a benefit in 90- day mortality. There 
are limited data on whether alteplase is associated with reduced mortality in patients with atrial fibrillation (AF)- related ischemic 
stroke whose mortality rate is relatively high. We sought to determine the association of alteplase with hemorrhagic transfor-
mation and mortality in patients with AF.
METHODS AND RESULTS: We retrospectively analyzed consecutive patients with acute ischemic stroke between 2015 and 2018 
diagnosed with AF included in the IAC (Initiation of Anticoagulation After Cardioembolic Stroke) study, which pooled data from 
stroke registries at 8 comprehensive stroke centers across the United States. For our primary analysis, we included patients 
who did not undergo mechanical thrombectomy (MT), and secondary analyses included patients who underwent MT. We 
used binary logistic regression to determine whether alteplase use was associated with risk of hemorrhagic transformation 
and 90- day mortality. There were 1889 patients (90.6%) who had 90- day follow- up data available for analyses and were in-
cluded; 1367 patients (72.4%) did not receive MT, and 522 patients (27.6%) received MT. In our primary analyses we found that 
alteplase use was independently associated with an increased risk for hemorrhagic transformation (odds ratio [OR], 2.23; 95% 
CI, 1.57– 3.17) but reduced risk of 90- day mortality (OR, 0.58; 95% CI, 0.39– 0.87). Among patients undergoing MT, alteplase 
use was not associated with a significant reduction in 90- day mortality (OR, 0.68; 95% CI, 0.45– 1.04).
CONCLUSIONS: Alteplase reduced 90- day mortality of patients with acute ischemic stroke with AF not undergoing MT. Further 
study is required to assess the efficacy of alteplase in patients with AF undergoing MT.
Key Words: alteplase ■ atrial fibrillation ■ mortality ■ stroke ■ thrombectomy
Intravenous alteplase improves outcomes in eligible patients with acute ischemic stroke, albeit with up to 6% risk of symptomatic intracranial hemorrhage in early trials
1 and lower rates with studies using real- 
world data.2 Faster alteplase treatment is associated 
with better functional outcomes.3 Clinical trials show 
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no benefit in 90- day mortality in patients treated with 
alteplase,4– 6 likely because of limited efficacy in pa-
tients with increased stroke severity.5
Patients with atrial fibrillation (AF) are at high risk for 
ischemic stroke, and stroke caused by AF is associ-
ated with increased risk of hemorrhagic transforma-
tion, functional disability, and mortality.2,7– 10 There are 
limited data on whether alteplase treatment improves 
mortality in patients with AF.
We sought to determine the association of alteplase 
treatment with the rate of hemorrhagic transformation 
and 90- day mortality in patients with AF- associated 
stroke.
METHODS
Institutional review board approval for the study was 
obtained from each of the study sites. Data from this 
study may be shared upon reasonable request to the 
corresponding author.
Study Sample
This is a multicenter retrospective study that ana-
lyzed data from the IAC (Initiation of Anticoagulation in 
Cardioembolic Stroke) study that included consecutive 
patients with nonvalvular AF hospitalized for acute is-
chemic stroke and treated at 8 comprehensive stroke 
centers in the United States for various periods across 
sites but between the years 2015 and 2018. The aim 
of the IAC study was to determine the optimal timing of 
initiation of anticoagulation in patients with acute car-
dioembolic stroke. Details of the study methodology 
have previously been described.11– 13 For this analysis, 
we included all patients in the IAC study except those 
who were lost to follow- up within 90 days. The index 
date was considered as the date stroke symptoms oc-
curred or last known normal time.
Independent Variable (Predictor)
The primary predictor in this study was treatment with 
intravenous alteplase.
Dependent Variables (Outcomes)
The coprimary study outcomes were 90- day mortal-
ity and early hemorrhagic transformation defined as 
any hemorrhagic transformation on a brain imaging 
(computed tomography or magnetic resonance im-
aging) in the first 24 to 48 hours and before initiation 
of anticoagulation.13 Secondary outcomes were num-
ber of passes in mechanical thrombectomy (MT) and 
successful reperfusion as determined by the treating 
interventionalist defined as modified thrombolysis in 
cerebral infarction score ≥2B.14
Covariates
The following covariates were collected as part of the 
IAC study and selected a priori based on biological evi-
dence to provide information about cardiovascular risk 
as well as potential clinical and imaging factors associ-
ated with ischemic or hemorrhagic complications.
Baseline Demographics and Clinical Variables
Baseline demographics and clinical variables included 
age, sex, history of hypertension, history of diabetes 
mellitus, history of hyperlipidemia, history of prior stroke 
or transient ischemic attack, active smoking, history 
of congestive heart failure, history of coronary artery 
CLINICAL PERSPECTIVE
What Is New?
• Intravenous alteplase is associated with re-
duced mortality in patients with atrial fibrillation 
not receiving mechanical thrombectomy.
What Are the Clinical Implications?
• Prospective studies are needed to confirm our 
findings and to determine whether alteplase indi-
cations can be safely expanded to patients with 
atrial fibrillation on oral anticoagulant therapy.
• Future studies are also needed to establish 
whether intravenous thrombolysis before me-
chanical thrombectomy is beneficial in cardi-
oembolic stroke.
Nonstandard Abbreviations and Acronyms
ASPECTS Alberta Stroke Program Early CT 
Score
DIRECT- MT Endovascular Thrombectomy With 
or Without Intravenous Alteplase 
in Acute Stroke
DOAC direct oral anticoagulant
IAC Initiation of Anticoagulation in 
Cardioembolic Stroke
MT mechanical thrombectomy
NIHSS National Institutes of Health 
Stroke Scale
SKIP Randomized Study of EVT With 
Versus Without Intravenous 
Recombinant Tissue- Type 
Plasminogen Activator in Acute 
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disease, admission National Institutes of Health Stroke 
Scale (NIHSS) score (abstracted from the medical re-
cord and performed by a certified provider), CHA2DS2- 
VASc score, and timing of initiating anticoagulation.
Home Medications
Home medications included aspirin and anticoagula-
tion therapy (warfarin or direct anticoagulants).
Laboratory and Imaging Variables
Laboratory and imaging variables included serum glu-
cose level on admission, infarct location (strictly pos-
terior circulation involvement versus not), and largest 
ischemic infarct size calculated on magnetic reso-
nance imaging largest ischemic stroke lesion volume 
determined on brain magnetic resonance imaging or 
computed tomography if magnetic resonance imaging 
was not obtained using the a×b×c/2 method.15
Statistical Analysis
Given the known overwhelming benefit of MT as well 
as inherently different stroke characteristics between 
patients eligible versus not eligible for MT, we stratified 
our analyses based on whether patients received MT 
or not. For univariate comparisons we used χ2 or Fisher 
exact test for categorical variables, as indicated, and t 
test or nonparametric (Mood’s median test) tests for 
continuous variables, as indicated. We created unad-
justed and adjusted binary logistic regression models 
to determine associations between alteplase use and 
the study outcomes adjusted for age and admission 
NIHSS score. No imputations were made for missing 
data. We used SPSS version 25.0 (IBM, Armonk, NY) 
to perform the analysis, and a 2- sided P<0.05 was 
considered statistically significant.
RESULTS
Out of 2084 patients included in the IAC study, 195 
were lost to follow- up at 90  days (Table  S1), leaving 
1889 patients for the analysis. The mean age was 
77.2±11.8 years, 51.8% were women, 32.0% had a his-
tory of stroke or transient ischemic attack, 35.6% were 
on anticoagulation before the ischemic stroke, 522 pa-
tients received MT, and 1367 patients did not receive 
MT. Figure 1 shows the flowchart of the study.
Patients Without Thrombectomy 
Treatment
Univariate Analyses in Patients Without 
Thrombectomy Treatment
Among patients not treated with MT, those who re-
ceived intravenous alteplase were less likely to have 
hypertension (78.7% versus 84.2%, P=0.03), diabetes 
mellitus (28.7% versus 37.4%, P=0.005), a prior stroke 
or transient ischemic attack (27.0% versus 36.2%, 
P=0.003), strictly posterior circulation infarcts (13.6% 
versus 21.4% P<0.001), or be on anticoagulation at 
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home (19.0% versus 41.9%, P<0.001). Conversely, 
patients treated with alteplase were more likely to be 
on aspirin at home (54.0% versus 45.5%, P=0.011) 
and have a higher initial median (interquartile range) 
NIHSS score (8 [4– 15] versus 6 [2– 14], P=0.002). Other 
baseline characteristics were not significantly different 
between the 2 groups (Table 1). The percentages of 
NIHSS score categories (≤5, 6– 10, 11– 15, >15) are dis-
played in Figure 2.
Patients receiving intravenous alteplase were more 
likely to have hemorrhagic transformation (20.3% ver-
sus 10.2%, P<0.001) but did have a lower 90- day mor-
tality rate (14.3% versus 19.8%, P=0.029) (Table 1).
Association Between Alteplase 
Treatment and Outcomes
In unadjusted analyses, intravenous alteplase use was 
associated with increased odds of hemorrhagic trans-
formation (odds ratio [OR], 2.24; 95% CI, 1.59– 3.16; 
P<0.001) but a reduced 90- day mortality (OR, 0.68; 
95% CI, 0.47– 0.96; P=0.030). These findings persisted 
in adjusted binary logistic regression showing that 
intravenous alteplase use was associated with increased 
odds of hemorrhagic transformation (adjusted OR, 2.14; 
95% CI, 1.49– 3.07; P<0.001) but a reduced 90- day mor-
tality (adjusted OR, 0.58; 95% CI, 0.39– 0.87; P=0.009). 
The association between alteplase treatment and re-
duced mortality persisted when certain mortality pre-
dictors such as diabetes mellitus and prior stroke were 
included in the model (adjusted OR, 0.58; 95% CI 0.38– 
0.87; P=0.009). Furthermore, the association between 
alteplase treatment and increased odds of hemorrhagic 
transformation persisted when admission glucose level 
and anticoagulation use were included in the model (ad-
justed OR, 2.21; 95% CI, 1.49– 3.07; P<0.001).
Patients With Thrombectomy Treatment
Univariate Analyses
Among patients treated with MT, patients who received 
intravenous alteplase were older (78.6±11.8 versus 
76.4±12.4 years, P=0.043), less likely to be on oral an-
ticoagulation at home (15.7% versus 47.4%, P<0.001), 
and had higher low- density lipoprotein LDL level re-
ported as median (interquartile range) (77 [59– 99] 
Table 1. Factors Among Patients Not Undergoing Mechanical Thrombectomy With Versus Without Alteplase
Nonalteplase, n=1067 Alteplase, n=300 P value
Age, y, mean±SD 77.0±11.5 77.6±12.0 0.468
Sex, % men 49.0% (523/1067) 52.7% (158/300) 0.267
Hypertension, % 84.2% (898/1067) 78.7% (236/300) 0.030
Diabetes mellitus, % 37.4% (399/1066) 28.7% (86/300) 0.005
Hyperlipidemia, % 58.0% (618/1066) 53.7% (161/300) 0.187
Prior stroke or TIA, % 36.2% (386/1067) 27.0% (81/300) 0.003
Active smoking, % 13.4% (126/938) 10.7% (28/262) 0.256
Congestive heart failure, % 27.0% (286/1046) 25.8% (77/298) 0.657
Coronary artery disease, % 33.8% (358/1059) 31.7% (95/300) 0.532
Peripheral vascular disease, % 7.7% (80/1038) 4.8% (14/294) 0.093
CHA2DS2- VASc, median (IQR) 5 (4– 6) 5 (3– 6) 0.104
Aspirin, % 45.5% (482/1059) 54.0% (162/300) 0.011
Anticoagulation at home, % 41.9% (444/1059) 19.0% (57/300) <0.001
NIHSS score, median (IQR) 6 (2– 14) 8 (4– 15) 0.002
Systolic blood pressure, mean±SD 152.8±29.1 150.2±28.4 0.164
Glucose, mg/dL, mean±SD 123 (103– 153) 124 (103– 149) 0.684
LDL, mg/dL, mean±SD 77 (59– 104) 83 (60– 110) 0.084
Posterior circulation, % 21.4% (208/971) 13.4% (37/277) <0.001
Interval to start anticoagulation, 
median (IQR)
3 (1– 7) 4 (2– 10) <0.001
Final infarct size ≤10 mL, % 38.2% (361/944) 40.8% (106/260) 0.473
Outcomes
Hemorrhagic transformation, % 10.2% (109/1067) 20.3% (61/300) <0.001
Death within 90 d, % 20.0% (212/1067) 14.3% (43/300) 0.029
Interval to start anticoagulation is the interval from index event to initiation of anticoagulation. Anticoagulation is any therapeutic anticoagulation (eg, direct oral 
anticoagulant, warfarin, heparin, lovenox). Largest ischemic infarct size was calculated on MRI as the largest ischemic stroke lesion volume determined on brain 
MRI or computed tomography that shows the infarct if MRI was not obtained using the a×b×c/2 method. IQR indicates interquartile range; LDL, low- density 
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Figure 2. The percentage of patients (y axis) with the National Institutes of Health Stroke Scale 
(NIHSS) score categories (x axis) in patients with or without alteplase stratified by whether they 
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versus 70 [52– 93], P=0.023). Other baseline charac-
teristics were not significantly different between the 2 
groups (Table 2). The percentages of NIHSS score cat-
egories (≤5, 6– 10, 11– 15, >15) are displayed in Figure 2.
Patients receiving intravenous alteplase tended to 
require fewer thrombectomy passes, though this was 
not statistically significant (median, 1; interquartile range, 
1– 2 versus median, 2; interquartile range, 1– 2; P=0.074). 
There was no significant difference in the rate of suc-
cessful recanalization (modified thrombolysis in cerebral 
infarction ≥2B, 91.8% versus 92.3%, P=0.729), hemor-
rhagic transformation (29.7% versus 33.7%, P=0.346), 
and 90- day mortality (28.9% versus 31.4%, P=0.566) 
between patients treated with alteplase versus patients 
not treated with alteplase (Table 2).
Association Between Alteplase 
Treatment and Outcomes
In unadjusted analyses, intravenous alteplase treatment 
was not associated with a difference in the odds of 
90- day mortality (OR, 0.89; 95% CI, 0.61– 1.30; P=0.537) 
or hemorrhagic transformation (OR, 0.83; 95% CI, 0.57– 
1.20; P=0.324). In adjusted binary logistic regression 
models, intravenous alteplase treatment was associated 
with a nonsignificantly lower 90- day mortality (adjusted 
OR, 0.68; 95% CI, 0.45– 1.04; P=0.077), but the odds of 
hemorrhagic transformation (adjusted OR, 0.82; 95% CI, 
0.56– 1.20; P=0.312) did not differ between the 2 groups. 
Results of the association between alteplase use and 
mortality remained unchanged when prior stroke and di-
abetes mellitus were included in the model (adjusted OR, 
0.74; 95% CI, 0.48– 1.13; P=0.164). Furthermore, results of 
the association between alteplase use and hemorrhagic 
transformation remained unchanged when admission 
glucose level and anticoagulation use were included in the 
model (adjusted OR, 0.72; 95% CI, 0.48– 1.08; P=0.108).
Additional Analyses
Because warfarin treatment with international normal-
ized ratio >1.7 and direct oral anticoagulant (DOAC) 
Table 2. Factors Among Patients Undergoing Mechanical Thrombectomy With Versus Without Alteplase
Nonalteplase (n=290) Alteplase (n=232) P value
Age, y, mean±SD 76.4±12.4 78.6±11.8 0.043
Sex, % women 43.4% (126/290) 44.8% (104/232) 0.790
Hypertension, % 81.9% (236/288) 80.2% (186/232) 0.652
Diabetes mellitus, % 27.9% (80/287) 23.8% (55/231) 0.315
Hyperlipidemia, % 54.2% (156/288) 45.7% (106/232) 0.064
Prior stroke or TIA, % 28.8% (83/288) 23.3% (54/232) 0.162
Active smoking, % 12.4% (31/250) 14.0% (29/207) 0.677
Congestive heart failure, % 23.9% (68/285) 24.9% (57/229) 0.836
Coronary artery disease, % 32.9% (95/289) 26.0% (60/231) 0.101
Peripheral vascular disease, % 7.3% (20/275) 4.2% (9/216) 0.178
CHA2DS2- VASc, median (IQR) 4 (3– 6) 4 (3– 6) 0.977
Aspirin, % 37.3% (107/287) 44.4% (103/230) 0.088
Anticoagulation at home, % 47.4% (136/287) 15.7% (36/230) <0.001
NIHSS, median, IQR 17 (11– 22) 18 (13– 23) 0.140
Systolic blood pressure, mean±SD 145.7±27.9 145.9±26.4 0.920
Glucose, median (IQR) 125 (106– 150) 119 (102– 144) 0.156
LDL, median (IQR) 70 (52– 93) 77 (59– 99) 0.023
Posterior circulation, % 8.6% (22/257) 4.3% (9/207) 0.091
Interval to start anticoagulation, 
median (IQR)
7 (2– 14) 7 (3.5– 14) 0.202
Largest infarct size ≤20 mL, % 50.6% (125/247) 55.4% (112/202) 0.342
Outcomes
No. of passes, median (IQR) 2 (1– 2) 1 (1– 2) 0.074
Successful recanalization, % 92.8% (244/263) 91.8% (191/208) 0.729
Hemorrhagic transformation, % 33.8% (98/290) 29.7% (69/232) 0.346
Death within 90 d, % 31.4% (91/290) 28.9% (67/232) 0.566
Interval to start anticoagulation is the interval from index event to initiation of anticoagulation. Anticoagulation is any therapeutic anticoagulation (eg, direct oral 
anticoagulant, warfarin, heparin, lovenox), and largest ischemic infarct size was calculated on MRI largest ischemic stroke lesion volume determined on brain 
MRI or computed tomography that shows the infarct if MRI was not obtained using the a×b×c/2 method. IQR indicates interquartile range; LDL, low- density 
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treatment within 48 hours before the index stroke rep-
resent contraindications for alteplase, we conducted 
additional analyses comparing mortality and hemor-
rhagic transformation rates in patients with AF on oral 
anticoagulant therapy with warfarin (n=349) or DOAC 
(n=327) who received alteplase versus those who did 
not.
As expected, patients on warfarin at home who 
did not receive alteplase had a significantly higher 
mean international normalized ratio level (1.7±0.8 ver-
sus 1.4±0.3, P<0.001). In models adjusted for age and 
NIHSS score, the mortality rate at 90 days was lower 
in those receiving intravenous alteplase as compared 
with those who did not receive alteplase (adjusted OR, 
0.29; 95% CI, 0.13– 0.67; P=0.004). Nevertheless, pa-
tients who received intravenous alteplase were more 
likely to have hemorrhagic transformation as compared 
with patients who were not treated with alteplase (ad-
justed OR, 3.37; 95% CI, 1.77– 6.43; P<0.001).
In patients on DOAC treatment, adjusted models 
(adjusting for age and NIHSS score) showed that the 
mortality rate at 90 days (adjusted OR, 0.51; 95% CI, 
0.12– 2.13; P=0.357) and hemorrhagic transformation 
(adjusted OR, 0.23; 95% CI, 0.03– 1.79; P=0.159) were 
not significantly different between groups.
Furthermore, to account for patient clustering by 
study site, we fit mixed- effects logistic regression 
models to our outcomes. The mixed- effects model es-
timates a separate intercept for each study site to ac-
count for between- hospital differences, such as case 
volume or proportion of cases treated with alteplase or 
MT as well as MT patient selection. In these analyses, 
our findings on associations between alteplase treat-
ment and 90- day mortality were essentially the same 
in patients not treated with thrombectomy (adjusted 
OR, 0.58; 95% CI, 0.38– 0.87; P=0.009) and in patients 
treated with thrombectomy (adjusted OR, 0.68; 95% 
CI, 0.45– 1.04; P=0.077).
Moreover, we performed interaction analyses to de-
termine whether the effect of alteplase on study out-
comes was different in patients with versus without MT 
treatment. In these analyses, the effect of alteplase on 
mortality was not significantly different in patients with 
versus without MT treatment (P- interaction=0.616). 
On the other hand, the effect of alteplase on the 
odds of hemorrhagic transformation was more pro-
nounced in patients with versus without MT treatment 
(P- interaction<0.001).
Finally, we performed matched analyses using pro-
pensity score matching (caliper set at 0.05, matched 
1:1) for hemorrhagic transformation (matched for age, 
NIHSS score, glucose, and anticoagulation use) and 
mortality (matched for age, NIHSS score, history of 
diabetes mellitus, and prior stroke). In these analy-
ses, alteplase treatment was associated with reduced 
mortality (OR, 0.48; 95% CI, 0.32– 0.73) but increased 
hemorrhagic transformation (OR, 1.71; 95% CI, 1.10– 
2.65) in patients not receiving MT (n=596 patients). On 
the other hand, alteplase was not associated with ei-
ther mortality (OR, 1.08; 95% CI, 0.69– 1.71) or hemor-
rhagic transformation (OR, 0.74; 95% CI, 0.48– 1.15) in 
patients receiving MT (n=366 patients).
DISCUSSION
We found that intravenous alteplase treatment was as-
sociated with a reduced 90- day mortality in patients 
with acute ischemic stroke in the setting of AF who 
were not treated with MT. Among patients undergo-
ing MT, there was a nonsignificantly lower number of 
passes and mortality in subjects that were treated with 
intravenous alteplase as compared with those who did 
not receive intravenous alteplase.
The decrease in mortality we observed in pa-
tients with AF who did not receive MT is consistent 
with prior studies encompassing all mechanisms of 
stroke.16 However, these findings are slightly different 
than other studies that showed no significant mor-
tality benefit of intravenous alteplase in patients with 
acute ischemic stroke and AF.17 It should be noted, 
however, that these studies were done before MT 
became a standard of care for patients presenting 
with acute large- vessel occlusion stroke. Intravenous 
alteplase treatment (versus none) without MT has 
limited benefit in patients with proximal large- vessel 
occlusion,18 which may explain the negative findings 
in some of the aforementioned studies. Conversely, 
stroke systems of care have considerably improved 
over time, leading to faster and safer administration 
of intravenous alteplase,2,19 which may account for 
some of the observed improved efficacy of intrave-
nous alteplase treatment in our study compared with 
the previous studies.20,21
We found a nonsignificantly lower mortality with 
alteplase in patients with AF who received MT. This 
is consistent with the pivotal thrombectomy trials, 
which did not demonstrate an effect on mortality or 
outcome.22,23 This is also in line with recent studies 
showing no significant added benefit of alteplase use 
in patients with proximal occlusion undergoing MT24,25 
and possibly related to the limited efficacy of alteplase 
in achieving successful reperfusion in patients with 
proximal large- artery occlusion. Nonetheless, our find-
ings highlight the need to further study this issue, par-
ticularly because stroke patients with AF have worse 
clinical outcomes after MT compared patients without 
AF.26
Mechanisms of Associations
There are several potential mechanisms by which in-
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patients with AF who were not selected for thrombec-
tomy in our study. Arguably, the main mechanism re-
lated to thrombolysis of clots within smaller27 and more 
distal28,29 vessels, which tend to respond favorably to 
alteplase. Unsurprisingly, there was increased risk of 
hemorrhagic transformation associated with intrave-
nous alteplase use, which is likely multifactorial and re-
lated to induced coagulopathy, reperfusion injury, and 
disruption of the blood– brain barrier.2,30 Presumably, 
most of these hemorrhages were asymptomatic given 
the overall lower mortality rate associated with al-
teplase use in our study. Conversely, another explana-
tion to our findings is that patients with extensive early 
signs of ischemia on initial brain imaging were not con-
sidered eligible for intravenous alteplase or thrombec-
tomy, thus explaining the increased mortality in the 
nonalteplase group.
Prior large meta- analyses have shown that ben-
efit of intravenous alteplase in patients undergoing 
thrombectomy extends to not only mortality but also 
improvement in functional outcome as well as in-
creased procedural success rates without increase 
in symptomatic hemorrhage.31,32 Most recently, the 
SKIP (Randomized Study of EVT With Versus Without 
Intravenous Recombinant Tissue- Type Plasminogen 
Activator in Acute Stroke With ICA and M1 Occlusion) 
study33 demonstrated a lack of noninferiority of fore-
going intravenous alteplase treatment in favor of di-
rect MT. Furthermore, the DIRECT- MT (Endovascular 
Thrombectomy With or Without Intravenous Alteplase 
in Acute Stroke) trial showed that endovascular ther-
apy alone was noninferior to endovascular therapy 
plus alteplase in achieving improved functional inde-
pendence at 90 days.23 In this trial, however, patients 
treated with alteplase were more likely to achieve suc-
cessful reperfusion.
Therapeutic Implications
The benefit of intravenous alteplase in acute stroke 
within 4.5 hours of onset is now well established, but 
up to 25% of eligible patients fail to receive alteplase 
treatment partially as a consequence of provider 
bias.34 Our analysis suggests that patients with AF 
with acute ischemic stroke should receive intravenous 
alteplase when eligible, despite the slightly higher risk 
of a hemorrhagic conversion within this subgroup. In 
addition, a large number of acute ischemic stroke pa-
tients have a contraindication to alteplase, of which 
being anticoagulated is not uncommon.35 In our 
analysis, premorbid anticoagulation for AF was more 
common in patients who did not receive intravenous 
alteplase, as would be expected. However, recent evi-
dence suggests that the use of warfarin for stroke pre-
vention in AF has become less frequent than the use 
of DOACs.36 Although DOACs have a favorable safety 
profile, one disadvantage is that rapid laboratory tests 
are not available to measure their therapeutic effect. As 
a result, patients with AF taking DOACs are not eligible 
to receive intravenous alteplase, unless they missed 
taking their medication within 24 to 48  hours of the 
index stroke. Although prethrombolysis DOAC rever-
sal has been reported,37,38 rapid reversal of warfarin or 
DOACs for intravenous alteplase treatment is presently 
not recommended because of the risk of additional 
thrombosis created by their rapid reversal.39 Because 
our analysis showed a mortality benefit for intravenous 
alteplase in patients with AF, it is appealing to further 
study the risk versus benefit of intravenous alteplase 
therapy in patients with AF on DOAC treatment.40 A 
recent meta- analysis indicated that intravenous throm-
bolysis in select patients treated with DOAC did not 
to increase the risk of symptomatic intracerebral hem-
orrhage.41 Furthermore, in patients with AF with high 
risk of stroke, such as extensive atherosclerosis of the 
cerebrovasculature or CHA2DS2- VASc >5, one con-
sideration would be left atrial appendage occlusion 
with subsequent antiplatelet therapy, which recent 
data suggest provides comparable efficacy compared 
with anticoagulation in stroke risk reduction.42,43 This 
will obviate the need for long- term anticoagulation and 
may potentially make these patients alteplase eligible if 
they were to have to an ischemic stroke.
Strengths and Limitations
Our study has several limitations including the retro-
spective and observational nature that may have in-
troduced bias. Although we adjusted for potential 
confounders, we cannot rule out residual confound-
ing. In addition, our findings may have been affected 
by contraindications to intravenous alteplase, which 
may have favored treatment of less- sick patients and 
those without large or already completed infarcts at 
presentation. However, this appears less likely, be-
cause in our study, patients treated with alteplase 
were older and had a higher initial NIHSS. Another 
limitation relates to the lack of data on several fac-
tors that have been associated with outcome after MT 
such as the time from symptom onset to treatment, 
perfusion imaging findings, ASPECTS (Alberta Stroke 
Program Early CT Score), collateral status, and loca-
tion of where large- vessel occlusion is. Moreover, we 
used the a×b×c/2 method to calculate infarct volume, 
which has been validated but is not commonly used 
in patients with ischemic stroke. Furthermore, the lack 
of information on time to treatment in patients who re-
ceived alteplase or MT, as well as possible heteroge-
neity in patient selection for thrombectomy across the 
study period, are additional limitations. These limita-
tions, however, are unlikely to affect our findings, be-
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treated with alteplase and does not apply to untreated 
patients, and thrombectomy treatment was being 
used in all participating centers during the study dura-
tion. In addition, follow- up imaging was performed at 
the discretion of the provider and thus may have con-
tributed to bias. Finally, the relatively high proportion of 
patients without a recorded 90- day modified Rankin 
Scale score precluded a more detailed analysis of the 
effect on functional disability.
Notable strengths of our study include its multi-
center design and inclusion of a large cohort of pa-
tients that provided real- world contemporary data in 
the era of MT treatment. In addition, using validated 
methodology, we captured data on infarct volume, 
which was not included in prior studies, particularly 
in those studying the efficacy of alteplase in patients 
without thrombectomy.
CONCLUSIONS
Intravenous alteplase use was associated with reduced 
mortality in patients with acute ischemic stroke not un-
dergoing MT. Larger prospective studies are needed to 
confirm our findings and to determine whether alteplase 
indication can be safely expanded to patients with AF 
on oral anticoagulant therapy, and future studies are 
needed to establish whether intravenous thrombolysis 
before MT is beneficial in cardioembolic stroke.
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Table S1. Baseline characteristics of patients who were lost to follow up. 
 Lost to follow up (n = 195) 
Age (years, mean ± SD) 77.3 ± 11.6 
Sex (% men) 43.6% (85) 
Hypertension (%) 76.9% (150) 
Diabetes (%) 26.2% (51) 
Hyperlipidemia (%) 62.6% (122) 
Prior stroke or TIA (%) 32.3% (63) 
Active smoking (%) 12.2% (23/188) 
Congestive heart failure (%) 25.6% (50) 
Coronary artery disease (%) 24.6% (48) 
Peripheral vascular disease (%) 5.8% (11/189) 
CHA2DS2-Vasc, median (IQR) 5 (3-6) 
NIHSS score, median (IQR) 6 (2-15) 
Alteplase treatment 29.7% (58) 
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